Name: 3D-Neuronavigation In Vivo Through a Patients Brain During a Spontaneous Migraine Headache (Video) | JoVE Journal
Uploaded: 2014-06-02T13:00:00.000+00:00
Duration: 10 min 39 s
Description: Explore 3D neuronavigation to study mu-opioid receptor activity during spontaneous migraine attacks using PET imaging with carbon 11 carfentanil. This immersive virtual reality method enables real-time brain exploration.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This work was supported by the following grants (DaSilva AF): National Institute of Health - National Institute of Neurological Disorders and Stroke - K23 NS062946, Dana Foundation's Brain and Immuno-Imaging Award, and the Migraine Research Foundation Research Grant Award. The authors acknowledge the PET Center Nuclear Medicine Technologists (Jill M. Rothley, Edward J. McKenna, Andrew R. Weeden, Paul Kison, and Caitlin Hendricks) and the personnel of Functional MRI Laboratory (Scott Peltier and Keith Newnham). Dr. Alexandre DaSilva, the principal investigator, had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis. The authors declare no conflicts of interest related to this study.

The study should be approved by the local Institutional Review Board, and by the Radioactive Drug Research Committee. The research subject gives written informed consent to participate in the study. The protocol is divided into three chronological steps:
<ol>
	<li>MRI session</li>
	<li>PET session during the ictal phase (headache) of migraine</li>
	<li>PET session during the interictal phase (no headache) of migraine</li>
</ol>
The patient is responsible for filling out a headache diary, and for confirming with the research group the occurrence of a migraine attack on the day of imaging session. Both, interictal and ictal, PET scans should be scheduled during separate mid-late follicular phases of the patient (5 to 10 days after the first day of menstrual bleeding), which in this case was tracked and calculated in advance by a gynecologist with expertise in the field (Y.R.S.).
1. MRI Session
<ol>
	<li>Preparing for the Experiment
	<ol>
		<li>Prior to preparing the subject for the scan, it is necessary to follow proper safety instructions due to the magnetic field of the MR scanner. All study personnel must be metal-free before entering the MR procedure room.</li>
		<li>Provide a copy of the Informed Consent Form, previously signed by the research volunteer during initial screening, to the MR technologist.</li>
	</ol>
	</li>
	<li>Preparing the Subject for the Scan
	<ol>
		<li>On the day of the MRI, ask the research subject to fill out a MRI safety screening form. This form is required for any MRI taken at the University of Michigan &#8211; fMRI lab. The questionnaire reinforces that the subject is also metal-free and does not have a medical condition that requires careful and special consideration (e.g., metallic foreign fragments, implanted mechanical/electrical device).</li>
		<li>Reassure that the participant understands the MR procedure, risks and benefits.</li>
		<li>Deliver the completed screening form to the MR technologist who will be assisting in the procedure.</li>
	</ol>
	</li>
	<li>Acquire a T1-weighted anatomical MRI scan during an interictal phase for the patient on a 3 Tesla scanner.
	<ol>
		<li>Use the following sequence parameters for the MRI acquisition:
		<ul>
			<li>A. Axial spoiled-gradient recalled (SPGR) 3D acquisition</li>
			<li>B. Bandwith = 15.63</li>
			<li>C. Repetition time [TR] = 9.2 msec</li>
			<li>D. Echo time [TE] = 1.9 msec</li>
			<li>E. Inversion recovery preparation 500 msec</li>
			<li>F. Flip angle = 15&#176;</li>
			<li>G. 25/26 FOV</li>
			<li>H. Number of Excitations [NEX] = 1</li>
			<li>I. 144 contiguous slices</li>
			<li>J. 1.0 mm slice thickness</li>
			<li>K. 256 x 256 matrix</li>
		</ul>
		</li>
	</ol>
	</li>
</ol>
2. Ictal PET Session
<ol>
	<li>Preparing for the Experiment
	<ol>
		<li>Prior to confirming the scan at the University Hospital, contact the subject to verify in which phase of the menstrual cycle she will be on the day of the scan. It is recommended to perform a PET scan during mid-late follicular phase (5 to 10 days following menstrual bleeding onset).</li>
		<li>Submit a request to the hospital to produce [11C]carfentanil, a short-life radiotracer with a selective affinity for &#181;-opioid receptors, using a cyclotron in the vicinity of the scan. The tracer must be produced 2 hr before the scan.</li>
		<li>On the day of the potential ictal PET scan, contact the subject 2&#160;hr&#160;before the appointment to confirm the presence of a spontaneous migraine attack. If a migraine attack is present, validate the migraine diagnosis following the International Classification of Headache Disorders. After diagnosis, assure that the participant is able to safely get to the hospital to undergo the scan. Provide transportation if the subject is not comfortable driving or if no designated driver is available.</li>
	</ol>
	</li>
	<li>Preparing the Subject for the Scan
	<ol>
		<li>When the participant arrives in the hospital, escort her to the PET suite for revalidation of diagnosis based on the International Classification of Headache Disorders. Prior to the scan, perform a urine drug test to confirm that the subject did not intake any substance that could interact with the tracer [11C]carfentanil, followed by an urine pregnancy test.</li>
		<li>Reaffirm that the participant understands the PET procedure, risks, and benefits.</li>
		<li>Deliver a copy of the Informed Consent Form, previously signed by the research volunteer during the initial screening, to the Nuclear Medicine technologist.</li>
		<li>Following the guidance of the Nuclear Medicine technologist, help the subject settle into the scanner.</li>
		<li>Have the subject undergo 1&#160;90 min PET scan using a Siemens HR+ scanner in 3D mode (reconstructed images have a full-width at half maximum (FWHM) resolution of ~5.5 mm-in-plane and 5.0 mm axially).</li>
		<li>For each [11C]carfentanil dose (555 MBq &#8804; 0.03 &#956;g/kg), administer fifty percent as a bolus with the remainder continuously infused over the course of the scan to achieve steady-state tracer levels approximately 35 min&#160;after tracer administration.</li>
		<li>Interictal PET session.</li>
		<li>Repeat Steps 2.2 - 2.6 during non-headache phase.</li>
	</ol>
	</li>
</ol>
3. PET Data Reconstruction
<ol>
	<li>Reconstruct PET images using interactive algorithms into a 128 x 128 pixel matrix in a 28.8 cm diameter field of view (FOV).</li>
	<li>Acquire 21&#160;image frames and co-register to one another to correct for motion during the scan.</li>
	<li>Obtain a 6 min transmission (68Ge source) scan prior to the PET scan for the purposes of attenuation correction.</li>
	<li>Convert the dynamic image data for each scan on a voxel-by-voxel basis into two sets of parametric images (10 - 40 min):
	<ol>
		<li>Use a tracer transport measure (K1 ratio) for coregistration and normalization procedures; and</li>
		<li>Use a receptor-related measure, BPND, proportional to Bmax (receptor concentration) to divide by Kd (receptor affinity).</li>
	</ol>
	</li>
	<li>Estimate these measures by using the reference region-based Logan graphical analysis with the occipital cortex as the reference region12.</li>
</ol>
4. PET Data Analysis
NOTE: Anatomically standardize images into template space using Statistical Parametric Mapping (SPM8) software following the sequence below.
<ol>
	<li>Co-register the MR scan and K1 scans.</li>
	<li>Normalize the MR scan to the Montreal Neurologic Institute (MNI) template brain using DARTEL.</li>
	<li>Apply the resulting deformation matrix to the PET images.</li>
	<li>Verify co-registration and normalization accuracy by comparing the transformed MR and PET images to the MNI atlas template.</li>
	<li>Region of Interest (ROI) analysis.</li>
</ol>
Examine the activity of several bilateral regions that are engaged during the processing of pain, including:
<ul>
	<li>A. Anterior/medial/posterior cingulate</li>
	<li>B. Insula</li>
	<li>C. Hippocampus</li>
	<li>D. Amygdala</li>
	<li>E. Caudate head/body</li>
	<li>F. Nucleus accumbens</li>
	<li>G. Putamen</li>
	<li>H. Lateral/medial globus pallidus</li>
	<li>I. Thalamus nuclei (ventral anterior, ventral posterior lateral/medial, lateral posterior, midline, lateral/medial dorsal)</li>
	<li>J. Periaqueductal gray matter (PAG)</li>
</ul>
<ol>
	<li>Define MarsBaR (in standardized space for each of these regions, with the exception of the PAG. Generate the PAG ROI by placing a 3 mm sphere at coordinates: right: 4, -28, -6; and left: -2, -28, -6. This PAG location was previously shown to have diffusional and connectivity alterations in migraine patients as compared to healthy controls13,14. 
	NOTE: Test-retest studies with [11C]carfentanil show reproducibility of BPND measures of well less than 10%, with most cortical regions being 3 - 5%15. The largest coefficients of variation (CoV = Std.Dev./Mean) are typically observed in the regions with the lowest binding, however, even in the cortical regions with lowest binding BPND CoV&#8217;s were ~0.5. Hence, percentage changes in ROI &#181;OR BPND between scans are only considered as significant when above 10%.</li>
</ol>
5. 3D-Neuronavigation
<ol>
	<li>Preparing for an 3D-IIN Experience
	<ol>
		<li>Organize the data provided in NIfTI volumetric data format as a stack of images with density and activation levels defined as 16 bit.</li>
		<li>Wear active LCD shutter glasses to enable the time sequential stereoscopic 3D effect. The shutter glasses operate through the blocking of one eye while the image for the other eye is shown on screen. The process then repeats for the other eye. This shuttering effect occurs at 110 Hz.</li>
		<li>Use a joystick for interactions with the simulation after being instructed on its use.</li>
		<li>Outfit the shutter glasses and joystick with reflective markers to enable precise 6DOF tracking of the objects in space via a Vicon motion capture system.</li>
	</ol>
	</li>
	<li>Display Aubject Activation Data
	<ol>
		<li>Use XML configuration files to define color mappings of density and activation levels, which are loaded when the application begins and shared with each computer in the cluster.</li>
		<li>Acquire 3-dimensional volumetric cells from the provided NIfTIdata set by way of Jugular&#8217;s internal loading functions and the &#8220;Niftilib&#8221; open source software library.</li>
		<li>Share resulting volumetric cells with each computer in the cluster to improve speed.</li>
		<li>Interpret Volumetric cells by an OpenGL shader (GLSL) that conducts ray marching and the displaying of voxels with varying colors and transparencies defined by previously shared color mapping XML configuration files.</li>
	</ol>
	</li>
	<li>Obtain the location through the Vicon system and use this to update drawn perspectives of the volumetric data on each screen.</li>
	<li>Record interactions and use them to dynamically adjust and cut planes through the data in order to navigate in the virtual space.</li>
</ol>
6. 3D-Immersive &#38; Interactive Neuronavigation (3D-IIN)
<ol>
	<li>Store subject activation data in the NIfTI data format, a volumetric data type that is interpreted using the Niftilib library.</li>
	<li>Obtain interactions and the location through a Vicon tracking system, a joystick device, and gestural input. Use this information to ensure the displayed image represents the correct vantage point, allowing for real-time exploration of the data set, and enable dynamic control for up to 3 arbitrary cutting planes using familiar movements and control schemes (Figure 1).</li>
</ol>

<ol><li>Stewart, W. F., Shechter, A., Rasmussen, B. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Migraine+prevalence.+A+review+of+population-based+studies%5BTitle%5D)+AND+%22Neurology%22%5BJournal%5D)">Migraine prevalence. A review of population-based studies.</a> Neurology. 44, (1994).</li>
<li>Lipton, R. B., Silberstein, S. D., Stewart, W. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+update+on+the+epidemiology+of+migraine%5BTitle%5D)+AND+%22Headache%22%5BJournal%5D)">An update on the epidemiology of migraine.</a> Headache. 34, 319-328 (1994).</li>
<li>Lipton, R. B., Bigal, M. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Migraine%3A+epidemiology%2C+impact%2C+and+risk+factors+for+progression%5BTitle%5D)+AND+%22Headache%22%5BJournal%5D)">Migraine: epidemiology, impact, and risk factors for progression.</a> Headache. , (2005).</li>
<li>Hu, X. H., Markson, L. E., Lipton, R. B., Stewart, W. F., Berger, M. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Burden+of+migraine+in+the+United+States%3A+disability+and+economic+costs.+Arch+Intern+Med%5BTitle%5D)+AND+%22Arch+Intern+Med%22%5BJournal%5D)">Burden of migraine in the United States: disability and economic costs. Arch Intern Med.</a> Arch Intern Med. 159, 813-818 (1999).</li>
<li>Lipton, R. B. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cutaneous+allodynia+in+the+migraine+population%5BTitle%5D)+AND+%22Ann+Neurol%22%5BJournal%5D)">Cutaneous allodynia in the migraine population.</a> Ann Neurol. 63, 148-158 (2008).</li>
<li>Fields, H. L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Understanding+how+opioids+contribute+to+reward+and+analgesia%5BTitle%5D)+AND+%22Reg+Anesth+Pain+Med%22%5BJournal%5D)">Understanding how opioids contribute to reward and analgesia.</a> Reg Anesth Pain Med. 32, 242-246 (2007).</li>
<li><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Opioid+Therapy+for+Migraine%5BTitle%5D)+AND+%22Headache%3A+The+Journal+of+Head+and+Face+Pain%22%5BJournal%5D)">Opioid Therapy for Migraine.</a> Headache: The Journal of Head and Face Pain. 47, 1371-1372 (2007).</li>
<li>Menon, S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+human+mu-opioid+receptor+gene+polymorphism+%28A118G%29+is+associated+with+head+pain+severity+in+a+clinical+cohort+of+female+migraine+with+aura+patients%5BTitle%5D)+AND+%22The+journal+of+headache+and+pain%22%5BJournal%5D)">The human mu-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients.</a> The journal of headache and pain. 13, 513-519 (2012).</li>
<li>Drinovac, V., Bach-Rojecky, L., Matak, I., Lackovic, Z. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Involvement+of+mu-opioid+receptors+in+antinociceptive+action+of+botulinum+toxin+type+A%5BTitle%5D)+AND+%22Neuropharmacology%22%5BJournal%5D)">Involvement of mu-opioid receptors in antinociceptive action of botulinum toxin type A.</a> Neuropharmacology. 70, 331-337 (2013).</li>
<li>Lipton, R. B., Bigal, M. E. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Opioid+therapy+and+headache%3A+a+cause+and+a+cure%5BTitle%5D)+AND+%22Neurology%22%5BJournal%5D)">Opioid therapy and headache: a cause and a cure.</a> Neurology. 62, 1662-1663 (2004).</li>
<li>Harris, R. E., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Decreased+central+mu-opioid+receptor+availability+in+fibromyalgia%5BTitle%5D)+AND+%22J+Neurosci%22%5BJournal%5D)">Decreased central mu-opioid receptor availability in fibromyalgia.</a> J Neurosci. 27, 10000-10006 (2007).</li>
<li>Logan, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Distribution+volume+ratios+without+blood+sampling+from+graphical+analysis+of+PET+data%5BTitle%5D)+AND+%22J+Cereb+Blood+Flow+Metab%22%5BJournal%5D)">Distribution volume ratios without blood sampling from graphical analysis of PET data.</a> J Cereb Blood Flow Metab. 16, 834-840 (1996).</li>
<li>Mainero, C., Boshyan, J., Hadjikhani, N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Altered+functional+magnetic+resonance+imaging+resting-state+connectivity+in+periaqueductal+gray+networks+in+migraine%5BTitle%5D)+AND+%22Ann+Neurol%22%5BJournal%5D)">Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine.</a> Ann Neurol. 70, 838-845 (2011).</li>
<li>DaSilva, A. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Interictal+alterations+of+the+trigeminal+somatosensory+pathway+and+periaqueductal+gray+matter+in+migraine%5BTitle%5D)+AND+%22Neuroreport%22%5BJournal%5D)">Interictal alterations of the trigeminal somatosensory pathway and periaqueductal gray matter in migraine.</a> Neuroreport. 18, 301-305 (2007).</li>
<li>Hirvonen, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Measurement+of+central+mu-opioid+receptor+binding+in+vivo+with+PET+and+%5B11C%5Dcarfentanil%3A+a+test-retest+study+in+healthy+subjects%5BTitle%5D)+AND+%22European+journal+of+nuclear+medicine+and+molecular+imaging%22%5BJournal%5D)">Measurement of central mu-opioid receptor binding in vivo with PET and [11C]carfentanil: a test-retest study in healthy subjects.</a> European journal of nuclear medicine and molecular imaging. 36, 275-286 (2009).</li>
<li>Cao, Y., Aurora, S. K., Nagesh, V., Patel, S. C., Welch, K. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Functional+MRI-BOLD+of+brainstem+structures+during+visually+triggered+migraine%5BTitle%5D)+AND+%22Neurology%22%5BJournal%5D)">Functional MRI-BOLD of brainstem structures during visually triggered migraine.</a> Neurology. 59, 72-78 (2002).</li>
<li>Afridi, S. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+PET+study+exploring+the+laterality+of+brainstem+activation+in+migraine+using+glyceryl+trinitrate%5BTitle%5D)+AND+%22Brain%22%5BJournal%5D)">A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate.</a> Brain. 128, 932-939 (2005).</li>
<li>Moulton, E. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Painful+heat+reveals+hyperexcitability+of+the+temporal+pole+in+interictal+and+ictal+migraine+States%5BTitle%5D)+AND+%22Cereb+Cortex%22%5BJournal%5D)">Painful heat reveals hyperexcitability of the temporal pole in interictal and ictal migraine States.</a> Cereb Cortex. 21, 435-448 (2011).</li>
<li>Burstein, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Thalamic+sensitization+transforms+localized+pain+into+widespread+allodynia%5BTitle%5D)+AND+%22Ann+Neurol%22%5BJournal%5D)">Thalamic sensitization transforms localized pain into widespread allodynia.</a> Ann Neurol. 68, 81-91 (2010).</li>
<li>Denuelle, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+PET+study+of+photophobia+during+spontaneous+migraine+attacks%5BTitle%5D)+AND+%22Neurology%22%5BJournal%5D)">A PET study of photophobia during spontaneous migraine attacks.</a> Neurology. 76, 213-218 (2011).</li>
<li>Denuelle, M., Fabre, N., Payoux, P., Chollet, F., Geraud, G. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hypothalamic+activation+in+spontaneous+migraine+attacks%5BTitle%5D)+AND+%22Headache%22%5BJournal%5D)">Hypothalamic activation in spontaneous migraine attacks.</a> Headache. 47, 1418-1426 (2007).</li>
<li>Weiller, C., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Brain+stem+activation+in+spontaneous+human+migraine+attacks%5BTitle%5D)+AND+%22Nat+Med%22%5BJournal%5D)">Brain stem activation in spontaneous human migraine attacks.</a> Nat Med. 1, 658-660 (1995).</li>
<li>Williamson, D. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Role+of+opioid+receptors+in+neurogenic+dural+vasodilation+and+sensitization+of+trigeminal+neurones+in+anaesthetized+rats%5BTitle%5D)+AND+%22Br+J+Pharmacol%22%5BJournal%5D)">Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats.</a> Br J Pharmacol. 133, 807-814 (2001).</li>
<li>Zubieta, J. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Regional+mu+opioid+receptor+regulation+of+sensory+and+affective+dimensions+of+pain%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Regional mu opioid receptor regulation of sensory and affective dimensions of pain.</a> Science. 293, 311-315 (2001).</li>
</ol>

The authors have nothing to disclose.

In this case report, actual migraine headache neuroimaging data was explored for the first time, in a fully immersive virtual 3D reality, which demonstrated a decrease in &#181;-opioid receptor availability (&#181;OR BPND). Reductions in &#181;OR BPND imply that there is a higher occupancy and/or a loss of &#181;-opioid receptors in the central nervous system. Acute reductions in &#181;OR BPND in pain-matrix regions during the ictal scan as compared to the interictal scan, are expected to occur as a consequence of the release of endogenous opioids interacting with &#181;ORs as a regulatory response to the ongoing pain, making less &#181;ORs accessible to the radiotracer.
The novelty of our ictal migraine neuroimaging study lies in the new 3D neuronavigation approach to investigate a patient&#8217;s actual brain data in virtual reality. PET radiotracer technology was used to measure changes in &#181;ORs availability with [11C]carfentanil. When examined during the headache event, the brains of migraineurs are usually scanned following an attack trigger (e.g., glyceryl trinitrate, photostimulation)16,17, or under the technical demand of a specific evoked stimulus (e.g., pain, brush, light, and odor)18-20. All those studies corroborate the knowledge that the disorder is associated with cortical and subcortical hyperexcitability during the headache phase. However, such a plethora of stimuli in the neuroimaging protocols introduces multiple factors that cloud our understanding of the sole impact of an acute migraine attack on the central nervous system. From the few previous functional studies without the presence of exogenous stimulation, there is indication of increased regional cerebral flow in areas such as the cingulate cortex, hypothalamus, and brainstem21, which can persist even after acute therapy22. Hitherto, the neuroimaging technologies applied have not allowed for the molecular characterization of neurotransmitter/receptor processes involved in the migraine attack, such as the endogenous &#181;-opioid mechanism, one of most important analgesic resources in the brain. Moreover, our method allowed these processes to be explored using 3D neuronavigation in a virtual environment.
The descending pain modulatory system is a complex network that regulates pain processing to a great extent via &#956;-opioid receptors throughout the brain, including spinal to supra-spinal areas. These areas are known to be involved in endogenous anti-nociception, stress-induced analgesia, and in the action of opioid drugs commonly used for chronic pain and migraine treatment. In fact, the dural neurogenic vasodilation associated with migraine can be inhibited by morphine and subsequently reversed by the opioid antagonist naloxone, indicating that the effects of morphine on neurogenic inflammation are mediated specifically via activation of &#181;-opioid receptors23. Interestingly, the magnitude of endogenous opioid/&#181;ORs regional activations in humans is related to the individual&#8217;s capacity to suppress sensory and affective elements of the pain experience24.
In our study, the brain regions that showed reductions in &#181;-opioid receptor availability during the ictal phase are responsible for both elements of the migraine headache experience and its modulation. They are the ACC, thalamus, basal ganglia (e.g., NAcc), hippocampus, and the PAG. In addition to sensitization due to abnormal trigeminal afferent traffic, one solid hypothesis for migraine pathophysiology is the dysfunction of the modulatory system. In this case, projections from/to brainstem structures, such as the PAG, where there is a high expression of opioid receptors, would inefficiently produce their anti-nociceptive effect on ascending sensory neurons. In addition, other higher cortical structures participate in this faulty pain-modulatory mechanism in migraine. A recent interictal resting-state study reported changes in the connectivity of migraineurs versus healthy controls in the ventrolateral PAG and most of the (sub)cortical structures in the modulatory pain system and correlated these with the frequency of the headache attacks13. The regions with connectivity changes found in this study are the same as those with changes in &#181;OR BPND found in our own study. The same PAG location was originally reported as encompassing microstructural neuroplasticity in migraineurs14, and here had a considerable decrease in &#181;OR BPND during the attack.
Further studies with larger cohorts are necessary to confirm and extend the findings presented in this case report. For instance, it is currently unknown why the system does not properly respond to the long-term use of exogenous opioids frequently prescribed in migraine clinics. Nonetheless, our study provides important mechanistic information, on the impact of a migraine headache in the &#181; -opioid system, and uses a novel 3D immersive and interactive neuronavigation (3D-IIN) approach for the first time. In the future, this exploratory 3D method could provide a much more immersive and interactive perspective for examining the brains of patients in research and the clinic.

Migraine is a chronic trigeminal pain disorder that affects nearly 16% of women and 6% of men in the United States and worldwide1-3. Repetitive migraine headache attacks have an impact on a large part of the patient&#8217;s existence, impairing quality of life and performance, costing billions of dollars in missed school/work days and healthcare utilization4. During the debilitating headache attacks, its sufferers have a marked increased sensitivity to noxious (hyperalgesia) and even nonnoxious stimuli (allodynia)5.
The &#181;-opioid neurotransmitter system is one of the principal endogenous pain modulatory mechanisms in our brain. It is involved in the regulation of experimental and clinical pain perception, as well as in the analgesic action of opioid drugs6-9&#160;which have been associated with the chronification of migraine attacks10. Recent advances in Positron Emission Tomography (PET) molecular imaging allow for the study of important molecular mechanisms in the brain of chronic pain patients in vivo11. In this study, despite the challenging logistics of synchronizing the aleatory and debilitating nature of the episodic attacks with the complexity of PET/radiotracer session setup, 3D neuronavigation was used for the first time to investigate &#181;OR availability in key pain-matrix regions of a patient&#8217;s brain during a spontaneous migraine headache.
Case Presentation
A 36 year-old Asian female was enrolled in the study. She presented with a 10 year history of migraine with visual aura. Right-sided migraine headaches occurred an average of 12 days per month, with moderate to severe pain intensity that would usually last for 72 hr (if untreated or unsuccessfully treated). There was an increased frequency of headache attacks around her menstrual cycle, which had a regular pattern throughout the study. Associated symptoms included: nausea, vomiting, photophobia, and phonophobia. During the regular headache attacks she did not present any autonomic symptoms. As treatment, she was managing her symptoms with pharmacological abortive therapy only, which was based on non-steroidal anti-inflammatory drugs, and there were no indications of medication overuse or opioid intake. The clinical examination during the screening visit was unremarkable and without abnormalities, and a review of systems was within normal limits. She was single with no children, and was not using contraceptive medication.

3d-neuronavigation in vivo through a patient's brain during a spontaneous migraine headache

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

A growing body of research, generated primarily from MRI-based studies, shows that migraine appears to occur, and possibly endure, due to the alteration of specific neural processes in the central nervous system. However, information is lacking on the molecular impact of these changes, especially on the endogenous opioid system during migraine headaches, and neuronavigation through these changes has never been done. This study aimed to investigate, using a novel 3D immersive and interactive neuronavigation (3D-IIN) approach, the endogenous &#181;-opioid transmission in the brain during a migraine headache attack in vivo. This is arguably one of the most central neuromechanisms associated with pain regulation, affecting multiple elements of the pain experience and analgesia. A 36 year-old female, who has been suffering with migraine for 10 years, was scanned in the typical headache (ictal) and nonheadache (interictal) migraine phases using Positron Emission Tomography (PET) with the selective radiotracer [11C]carfentanil, which allowed us to measure &#181;-opioid receptor availability in the brain (non-displaceable binding potential - &#181;OR BPND). The short-life radiotracer was produced by a cyclotron and chemical synthesis apparatus on campus located in close proximity to the imaging facility. Both PET scans, interictal and ictal, were scheduled during separate mid-late follicular phases of the patient's menstrual cycle. During the ictal PET session her spontaneous headache attack reached severe intensity levels; progressing to nausea and vomiting at the end of the scan session. There were reductions in &#181;OR BPND in the pain-modulatory regions of the endogenous &#181;-opioid system during the ictal phase, including the cingulate cortex, nucleus accumbens (NAcc), thalamus (Thal), and periaqueductal gray matter (PAG); indicating that &#181;ORs were already occupied by endogenous opioids released in response to the ongoing pain. To our knowledge, this is the first time that changes in &#181;OR BPND during a migraine headache attack have been neuronavigated using a novel 3D approach. This method allows for interactive research and educational exploration of a migraine attack in an actual patient's neuroimaging dataset.

The patient presented to the hospital with a right temporal and occipital pulsating headache, with intensity of 6 on a 0-10 pain scale. She was having her typical migraine headache, however without aura. It had initiated upon awakening 5 hr before the (ictal) PET session, and she managed to tolerate it without any abortive pharmacotherapy. To her knowledge, the headache was not evoked by any triggering factor (e.g., alcohol, sleep deprivation). No autonomic symptoms were reported, but photophobia and phonophobia were present. Following initiation of the ictal PET session the headache intensity escalated, reaching severe levels (9 on a 0-10 pain scale) 60 min into the study; progressing to nausea and vomiting at the end of the scan session. Decrease in µOR BPND was noticed in the brain of the patient during the spontaneous migraine headache (ictal phase), as compared to the baseline (interictal phase) (Figure 2). There were patent reductions in µOR BPND in the main pain-matrix regions of the endogenous µ-opioid system, including the following thalamus nuclei: right lateral dorsal (11, -19, -16: 10.2%), right medial dorsal (6, -17, -8: 11.1%), right midline (8, -19, -16: 27%), and ventral anterior (9, -9, -12: 12.0%). In addition, changes were found in the right anterior (8, 35, 14: 13.7%) and left posterior cingulate cortex (-5, -44, 23: 11.8%), left caudate body (-11, 6, 15: 12.0%), medial globus pallidus (right: 16, -4, -3: 16.2%; left: -14, -4, -3: 22.6%), left nucleus accumbens (-9, -11, -7: 10.5%), and hippocampus (right: 30, -22, -14: 12.6%; left: -30, -22, -14: 11.5%). There was an increase in µOR BPND only in the left amygdala (-23, -4, -19: 11.7%). In the brainstem, the significant ictal reduction in µOR BPND extended from the rostral to caudal periaqueductal gray matter (PAG) (right: 4, -28, -6: 15.1%; left: -2, -28, -6: 14.6%) (Figure 3). However, the global hemispheric percentage changes in the µOR BPND during the migraine attack were modest (right: 8.5%; left: 8.29%), indicating that the decreases in the µOR BPND were specific to the pain-matrix structures in the brain.
<img alt="Interactive 3D brain model visualization using virtual reality for neurological data analysis." fo:content-width="5in" src="/files/ftp_upload/50682/50682fig1highres.jpg" width="500" data-altupdatedat="1787630408000" data-alt="Figure 1"> 
Figure 1. Full Virtual Reality 3D Data Navigation of a Migrainous Brain. For the first time actual migraine neuroimaging data was explored in a fully immersive 3D virtual reality, which includes unrestricted navigation through the data (by students, clinicians, and researchers) regarding availability of µ-opioid receptors (µOR BPND) in the brain during the migraine headache attack in vivo.
<img alt="Migraine study brain PET scan diagram showing μ-opioid receptor availability change during attack." fo:content-width="5in" src="/files/ftp_upload/50682/50682fig2highres.jpg" width="500" data-altupdatedat="1787630408000" data-alt="Figure 2"> 
Figure 2. μ-Opioid Brain Profile of a Migraine Headache in vivo. The ictal phase (lower row) – headache phase - shows a decrease in μ-opioid receptor availability (µOR BPND) in the pain-matrix regions (Threshold value, DV = 4.50). This result possibly represents an increase in endogenous μ-opioid release during the migraine attack, as a regulatory response to the ongoing severe headache. Key words: thalamus (Thal), nucleus accumbens (Nac), and anterior cingular cortex (ACC).
<img alt="Neuroimaging diagram of μ-opioid receptor availability change in PAG during migraines." fo:content-width="5in" src="/files/ftp_upload/50682/50682fig3highres.jpg" width="500" data-altupdatedat="1787630408000" data-alt="Figure 3"> 
Figure 3. Midbrain/Pons/Medulla μ-Opioid Receptor Availability During a Migraine Attack in vivo. The ictal phase (right column) – headache phase - shows a decrease in μ-opioid receptor availability along the periaqueductal gray matter (PAG) (Threshold value, DV = 4.50), as compared to the interictal phase (left column) – non-headache phase. Key words: PAG: r - rostral; m - medial; c - caudal.

In this study, the authors report for the first time a novel 3D-Immersive &#38; Interactive Neuronavigation (3D-IIN) through the impact of a spontaneous migraine headache attack in the &#956;-opioid system of a patient's brain in vivo.

A growing body of research, generated primarily from MRI-based studies, shows that migraine appears to occur, and possibly endure, due to the alteration ...

The overall goal of this procedure is to investigate using a novel 3D neuronavigation. Approach the endogenous mu opioid transmission in the brain during a spontaneous migraine headache attack in vivo. This is accomplished by first scanning a migraine patient in a typical headache and non headache phase, using positron emission tomography with a selective radio tracer, carbon 11 carfentanil, which allows us to measure mu opioid receptor availability in the brain.The second step is to verify co-registration and normalization accuracy by comparing the transformed MR and PET images to the MNI Atlas template. In order to apply region of interest ROI analysis, the final step is to organize and store subject activation data in the nifty data format to display the volume in a fully immersive multi-screen clustered configuration. Ultimately, the 3D neuro navigation system allows for real-time exploration of the dataset and enables dynamic control and dissection of the neuro imaging data of the patient during a migraine attack in a virtual reality environment.The main advantage of this technique over existing methods is that it permits the full interaction and navigation in real time through the brain of a patient during a migraine attack. This method can help answer key questions in the migraine field, such as which areas in the brain are more or less active during a migraine attack At molecular level with in vivo using carbon 11 corfe, a specific MU opioid visual tracer tapping into one of the main analog mechanisms in the brain. Generally, individuals new to this method will struggle because of the complexity to adapt the neuroimaging data and the challenge of making a fully interactive virtual reality environment.Virtual, virtual reality, The software was developed to create a complete immersive experience. The computer uses advanced motion tracking equipment to track the user's point of view and gestures in the virtual reality space. Special shutter glasses deliver separate left and right perspectives to the brain, which merged to form the perception of A 3D experience for the user, and they're really cool.Prior to preparing the subject for this scans in this protocol, first obtain written and informed consent. Then on the day of the MRI scan, have the research subject fill out an MRI safety screening form During an interictal phase for the patient, acquire a high resolution T one weighted anatomical MRI image on a three Tesla MRI scanner. A one millimeter slice thickness is recommended for this scan.Then prior to confirming the date for the subject's PET scan, contact the subject to verify in which phase of the menstrual cycle she will be on the day of the scan. It is recommended to perform the PET scan during mid to late follicular phase. Once the scan date is confirmed, submit a request to produce carbon 11 carfentanil a short life radio tracer with a selective affinity for mu opioid receptors using a cyclotron in the vicinity of the scanner site.Note that this tracer must be produced two hours before the scan. Then on the day of the potential ictal PET scan, contact the subject two hours before the appointment to confirm the presence of a spontaneous migraine attack. If a migraine attack is present, validate the migraine diagnosis following the international classification of headache disorders.After diagnosis, confirm that the participant is able to safely go to the hospital to undergo the scan. Provide transportation if the subject is not comfortable driving or if no designated driver is available. When the participant arrives at the hospital, escort her to the pet suite for revalidation of diagnosis using the same international criteria.Then before the scan perform a urine drug test to confirm that the subject did not take any substance that could interact with the tracer as well as a pregnancy test. Confirm that the participant understands the PET procedure risks and benefits, and verify informed consent following the guidance of the nuclear medicine technologist. Help the subject to settle in the scanner for each dose of tracer.Administer 50%as a bolus with the remainder continuously infused over the course of the scan to achieve steady state tracer levels. Approximately 35 minutes after tracer administration perform one 90 minute PET scan here a Siemens HR plus scanner in 3D mode is used. The reconstructed images should have a full width at half maximum resolution of about 5.5 millimeters in plain and 5.0 millimeters.Axially also run an INTERICTAL PET scan by repeating these steps during a non headache phase during the following menstrual cycle. Then reconstruct the PET data and perform data analysis including normalization and region of interest analysis. See the text accompanying this protocol for more detail.To prepare for the 3D interactive neuronavigation experience, first, organize the data provided in nifty volumetric data format as a stack of images with density and activation levels defined as 16 bit. Wear active LCD shutter glasses to enable the time sequential stereoscopic 3D effect. The shutter glasses operate by blocking the image for one eye while the image for the other eye is displayed.The process alternates between eyes to generate a 3D effect and occurs at 110 hertz. Use a joystick for interactions with the simulation and instructions on its use outfit, both the shutter glasses and joystick with reflective markers to enable precise six DOF tracking of the objects in space via a vicon motion capture system. Next, display the subject activation data use XML configuration files to define color mappings of density and activation levels, which are loaded when the application begins and are shared with each computer in the cluster.Acquire three dimensional volumetric cells from the provided nifty dataset by way of jugulars internal loading functions and the nifty lab open source software library. Typical loading time is less than one minute, but sharing resulting volumetric cells with each computer and the cluster will improve speed. Interpret volumetric cells by an open GL shader that conducts ray marching and displays voxels with varying colors and transparencies defined by the previously shared color mapping XML configuration files.Obtain the location through the Vicon motion capture system and use this to update the drawn perspectives of the volumetric data on each screen. Record interactions and use them to dynamically adjust and cut planes through the data and to navigate in the virtual space for three dimensional interactive neuro navigation. First store the subject activation data in the nifty data format, a volumetric data type that is interpreted using the nifty live library.Then to display the volume in a fully immersive multi-screen clustered configuration, apply the volumetric data to the back faces of a scaled cube and render using a single pass GL SL shader. The shader array marches through the volume displaying voxels with varying colors and transparencies based on density and activation levels. Obtain interactions and the location through the tracking system, joystick device and gestural input.Use this information to ensure the displayed image represents the correct vantage point, allowing for real time exploration of the dataset. Also enable dynamic control for up to three arbitrary cutting planes using familiar movements and control schemes. Here we can see an mu opioid brain profile of a migraine headache in vivo.The ictal or headache phase shows a decrease in mu opioid receptor availability in the pain matrix regions. This possibly represents an increase in endogenous mu opioid release during the migraine attack as a regulatory response to the ongoing severe headache. Here we can see an example of midbrain, pons and medulla mu opioid receptor availability during a migraine attack in vivo.The ictal headache phase shows a decrease in mu opioid receptor availability along the peri aqueduct gray matter as compared to the interictal non headache phase. The implications of this technique extend to therapy of migraine because it can define with more accuracy, potential targets in the brain for future treatments, including neuromodulation. Though this method can provide insight into migraine, it can also be applied to other neurological disorders such as neurologists, depression and addiction.The combination of 3D neuro navigation and neuroimaging allows for researchers, clinicians, and educators in the field of pain, neuroscience to explore the brain in a much more interactive and immersive virtual environment. The results presented demonstrate important mechanistic information on the impact of migraine headache on the MO opioid system.

3d-neuronavigation-vivo-through-patient-s-brain-during-spontaneous

Research

JoVE Journal

Medicine

This study is designed to test the hypothesis that neuronavigational system-guided transcranial magnetic stimulation has higher accuracy for targeting the intended target as demonstrated by eliciting a greater degree of virtual aphasia in healthy subjects, measured by delay in reaction time to picture naming.

Neuronavigation-guided Repetitive Transcranial Magnetic Stimulation for Aphasia

We describe the steps to use our custom designed software for image integration, visualization and planning in epilepsy surgery.

A Pipeline for 3D Multimodality Image Integration and Computer-assisted Planning in Epilepsy Surgery

To evaluate morphological changes of cranial nerves such as loss of neural structures or swelling of cranial nerves in Menière's Disease (MD) or in healthy persons in vivo, a protocol of evaluation has been developed using magnetic resonance imaging (MRI). Additional MRI-based confirmation of MD was performed.

In Vivo Morphometric Analysis of Human Cranial Nerves Using Magnetic Resonance Imaging in Meni&#232;re's Disease Ears and Normal Hearing Ears

This article provides an overview of a multi-modal brain mapping program designed to identify regions of the brain that support critical cognitive functions in individual neurosurgery patients.

Translational Brain Mapping at the University of Rochester Medical Center: Preserving the Mind Through Personalized Brain Mapping

We present a protocol to integrate diffusion MRI tractography in patient work-up to endoscopic endonasal surgery for a skull base tumor. The methods for adopting these neuroimaging studies in the pre- and intra-operative phases are described.

Role of Diffusion MRI Tractography in Endoscopic Endonasal Skull Base Surgery

The most notable symptom of migraine is severe head pain, and it is hypothesized that this is mediated by sensory neurons innervating the meninges. Here, we present a method to locally apply substances to the dura in a minimally invasive manner while using facial hypersensitivity as an output.

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Navigated repetitive transcranial magnetic stimulation is a highly efficient non-invasive tool for mapping speech-related cortical areas. It helps in designing brain surgery and speeds up the direct cortical stimulation conducted during the surgery. This report describes how to perform speech cortical mapping reliably for preoperative evaluation and research.

Study Design for Navigated Repetitive Transcranial Magnetic Stimulation for Speech Cortical Mapping

This protocol describes the method of neuronavigated electrode placement for focal, transcranial direct current stimulation (tDCS) administered during functional magnetic resonance imaging (fMRI).

Neuronavigated Focalized Transcranial Direct Current Stimulation Administered During Functional Magnetic Resonance Imaging

This paper describes the standardized induction of Long-term Potentiation-like cortical plasticity using repetitive stimulation protocols, followed by applying single-pulse transcranial magnetic stimulation guided by a neuronavigation system to evaluate synaptic plasticity.

Standardized Induction and Assessment of Long-term Potentiation-like Cortical Plasticity Using Transcranial Magnetic Stimulation

Here, we describe a standardized protocol for motor mapping using nTMS combined with diffusion tensor imaging (DTI)-based reconstruction of the corticospinal tract (CST). The protocol is reproducible, clinically feasible, and readily integrable into routine clinical workflows, providing a robust and valuable framework for motor pathway assessment, neuroplasticity research, and rehabilitation planning.

A Standardized Protocol for Functional Motor Mapping Using Navigated Transcranial Magnetic Stimulation

Explore 3D neuronavigation to study mu-opioid receptor activity during spontaneous migraine attacks using PET imaging with carbon 11 carfentanil. This immersive virtual reality method enables real-time brain exploration.

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Explore More Videos